

42534-733\_601\_SL  
SEQUENCE LISTING

<110> GUARDANT HEALTH, INC.

<120> METHODS FOR MULTI-RESOLUTION ANALYSIS OF CELL-FREE NUCLEIC ACIDS

<130> 42534-733.601

<150> 62/489,391

<151> 2017-04-24

<150> 62/4468,201

<151> 2017-03-07

<150> 62/402,940

<151> 2016-09-30

<160> 11

<170> PatentIn version 3.5

<210> 1

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

<400> 1

gctaccccc gcagcagcag cagcagcagc agcaac

36

<210> 2

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 2

Arg Tyr Pro Pro Gln Gln Gln Gln Gln Gln Gln Gln

1

5

10

<210> 3

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 3

|     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Ala | Thr | Pro | Arg | Ser | Ser | Ser | Ser | Ser | Ser | Ser | Asn |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |

<210> 4

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 4

|     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Leu | Pro | Pro | Ala | Ala | Ala | Ala | Ala | Ala | Ala | Ala | Thr |
| 1   |     |     | 5   |     |     |     |     |     | 10  |     |     |

<210> 5

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic peptide

<400> 5

|     |     |     |     |     |     |     |     |     |     |     |     |     |
|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Arg | Tyr | Pro | Pro | Gln | Gln | Gln | Gln | Gln | Gln | Gln | Gln | Arg |
| 1   |     |     |     | 5   |     |     |     |     | 10  |     |     |     |

<210> 6

<211> 12

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic oligonucleotide

<400> 6

gcatacgtga tg

12

<210> 7

&lt;211&gt; 32

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
oligonucleotide

&lt;400&gt; 7

gtacccttgt cccaggaag catacgtgat gg

32

&lt;210&gt; 8

&lt;211&gt; 9

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 8

Arg Thr Leu Val Pro Arg Lys His Thr  
1 5

&lt;210&gt; 9

&lt;211&gt; 11

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 9

Val Pro Leu Ser Pro Gly Ser Ile Arg Asp Gly  
1 5 10

&lt;210&gt; 10

&lt;211&gt; 10

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

<223> Description of Artificial Sequence: Synthetic  
peptide

&lt;400&gt; 10

Tyr Pro Cys Pro Gln Glu Ala Tyr Val Met  
1 5 10

42534-733\_601\_SL

<210> 11

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Synthetic  
peptide

<400> 11

Glu Ala Tyr Val Met

1 5